Biora Therapeutics Showcases Innovations at Peptide Symposium
Biora Therapeutics Highlights Advances at Peptide Symposium
Biora Therapeutics, Inc. (Nasdaq: BIOR) has announced an exciting opportunity for the biotech industry at the upcoming 19th Annual Peptide Therapeutics Symposium, where company leadership will engage with peers and experts in the field. This event, scheduled for October 22–23, 2024, will provide insights into the latest advancements in peptide research and drug development.
Details of Biora's Presentation
During the symposium, Biora's Head of Research, Sharat Singh, PhD, will present a captivating session titled Empowering Peptide Self-Administration with Needle Free Smart Capsules. This presentation is set for October 22, 2024, from 2:30 PM to 3:00 PM PT and will delve into Biora's innovative approach to peptide administration without the need for traditional needles.
About the Peptide Therapeutics Symposium
The Peptide Therapeutics Symposium serves as a significant platform for experts from academic and biopharmaceutical backgrounds to gather. Here, discussions focus on breakthroughs in peptide technologies, exploring new methodologies that can enhance drug discovery and the development of therapeutic candidates. This convergence of minds allows for a rich exchange of ideas that can propel the industry forward.
Innovative Platforms at Biora Therapeutics
Biora Therapeutics is at the forefront of innovation in therapeutic delivery, uniquely positioned with two significant platforms aimed at transforming patient experiences. The first is the NaviCap™ platform for colon-targeted treatment of IBD. This groundbreaking technology aims to enhance patient outcomes by delivering treatments directly to the affected areas of the gastrointestinal tract.
The second platform is the BioJet™ platform for oral delivery of large molecules, which is designed to replace invasive injections with a needle-free oral solution. This advancement is particularly vital for better management of chronic diseases, making treatments more accessible and less intimidating for patients.
For Further Information
Patients and interested individuals can visit bioratherapeutics.com for detailed insights about ongoing research and the latest news from Biora Therapeutics. Additionally, those interested can follow the company's developments on social media platforms like LinkedIn and X.
Frequently Asked Questions
What is the Peptide Therapeutics Symposium?
The Peptide Therapeutics Symposium is an event that gathers leaders in peptide research to discuss advancements in drug discovery and therapeutic candidates.
Who presents at the symposium?
Biora Therapeutics will present at the symposium, with Dr. Sharat Singh discussing needle-free self-administration methods.
What are the key platforms developed by Biora Therapeutics?
Biora has developed the NaviCap™ platform for IBD treatment and the BioJet™ platform for oral delivery of large molecules.
When is Biora’s presentation scheduled?
The presentation is on October 22, 2024, from 2:30 PM to 3:00 PM PT.
How can I find out more about Biora Therapeutics?
Visit Biora's official website at bioratherapeutics.com for the latest news and information.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.